In recent years, EGFR-targeted therapy has been reported to not only inhibit tumor cells, but also reduce the secretion of GM-CSF, CCL3, TGF-α, bFGF, and VEGF, further affecting the tumor microenvironment [23, 24]. This evidence concerns the gene CCL3 and neoplasm.